Based on real-world data, Johnson & Johnson (NYSE:JNJ) announced Wednesday its prostate cancer therapy Erleada (apalutamide) ...

According to findings from the TALAPRO-2 study, the combination led to significant and meaningful improvements in overall ...

Johnson & Johnson reveals Erleada's 23% lower risk of death over Xtandi in a real-world study of prostate cancer patients, ...

Kirkland & Ellis has successfully defended the validity of a pharmaceutical company's patent in London's High Court, ...

On September 13, 2024, ESSA Pharma, Inc. (NASDAQ:EPIX) announced that updated Phase 1/2 clinical trial data for masofaniten (formerly EPI-7386) in combination with enzalutamide (Enz) was presented ...

Pfizer Inc. (NYSE: PFE) today announced positive topline results from the final prespecified overall survival (OS) analysis ...

Talazoparib plus enzalutamide significantly improved overall survival in mCRPC patients, including those with HRR gene mutations. The treatment's safety profile aligns with known data for talazoparib ...

Investigators examined overall survival among real-world patients with metastatic prostate cancer (mCSPC) initiating enzalutamide vs apalutamide.

Zydus Lifesciences share price trading maginally lower in the opening trade on October 3 despite the company received ...

(RTTNews) - Johnson & Johnson (JNJ), Wednesday announced results from a head-to-head study, demonstrating statistically significant overall survival benefit in patients on Erleada at 24 months ...

BARCELONA, Spain — Adding bone-targeting radium-223 (Ra223) to the androgen receptor pathway inhibitor enzalutamide (Xtandi) in patients with metastatic castration-resistant prostate cancer and ...

Abiraterone acetate plus prednisone and enzalutamide improve overall survival (OS) and radiological progression-free survival (rPFS) in docetaxel-pretreated patients. Abiraterone acetate plus ...